Tempest Therapeutics Inc (TPST) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tempest Therapeutics Inc (TPST) has a cash flow conversion efficiency ratio of -9.243x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.60 Million) by net assets ($822.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Tempest Therapeutics Inc (TPST) defensive interval to measure how many days the company can operate on defensive assets alone.
Tempest Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Tempest Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tempest Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tempest Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CHARBONE HYDROGEN CORP.
F:K47
|
0.315x |
|
PODIUM MINERALS
F:55D
|
N/A |
|
Tungray Technologies Inc Class A Ordinary Shares
NASDAQ:TRSG
|
-0.166x |
|
China Times Publishing Co
TWO:8923
|
0.071x |
|
UMS Holdings Bhd
KLSE:7137
|
0.018x |
|
Panostaja Oyj
HE:PNA1V
|
0.261x |
|
Holista Colltech Ltd
AU:HCT
|
-0.382x |
|
JERICHO OIL
F:JLM
|
-0.018x |
Annual Cash Flow Conversion Efficiency for Tempest Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Tempest Therapeutics Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see TPST stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.67 Million | $-26.82 Million | -4.022x | -132.93% |
| 2024-12-31 | $19.13 Million | $-33.03 Million | -1.727x | -68.96% |
| 2023-12-31 | $26.77 Million | $-27.36 Million | -1.022x | +40.43% |
| 2022-12-31 | $18.11 Million | $-31.07 Million | -1.716x | -138.72% |
| 2021-12-31 | $36.12 Million | $-25.96 Million | -0.719x | -359.98% |
| 2020-12-31 | $-68.79 Million | $-19.02 Million | 0.276x | +140.15% |
| 2019-12-31 | $59.87 Million | $-41.22 Million | -0.689x | -112.90% |
| 2018-12-31 | $73.12 Million | $-23.65 Million | -0.323x | +76.18% |
| 2017-12-31 | $14.98 Million | $-20.34 Million | -1.358x | -137.97% |
| 2016-12-31 | $108.22 Million | $-61.73 Million | -0.570x | -43.90% |
| 2015-12-31 | $126.85 Million | $-50.29 Million | -0.396x | +28.30% |
| 2014-12-31 | $55.33 Million | $-30.59 Million | -0.553x | -27.42% |
| 2013-12-31 | $41.70 Million | $-18.09 Million | -0.434x | -19.49% |
| 2012-12-31 | $30.72 Million | $-11.16 Million | -0.363x | -- |
About Tempest Therapeutics Inc
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-14… Read more